Cryoablation and Arterial Infusion of SD-101 in Combination with Durvalumab and Tremelimumab

Recruiting

Phase 1

Cryoablation & SD-101Cryoablation and Arterial Infusion of SD-101 in Combination with Durvalumab and Tremelimumab

Sponsor:

UCLA

Code:

NCT06710223

Conditions

Hepatocellular Carcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

SD-101

Cryotherapy

Tremelimumab

Durvalumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-05-01. This information was provided to ClinicalTrials.gov by University of California, San Diego on 2025-02-11.